---
title: "What's Going On With MIRA Pharma Stock Tuesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280327824.md"
description: "MIRA Pharmaceuticals (NASDAQ: MIRA) is experiencing a pullback in premarket trading after a 21.74% surge on Monday, following positive preclinical data for Mira-55, which showed no CNS side effects. The company aims to submit an IND for Mira-55, targeting inflammatory pain treatment. The findings suggest Mira-55 could provide therapeutic benefits without CNS liabilities, potentially tapping into a market projected to reach $70.3 billion by 2030. Currently, MIRA shares are down 5.77% at $1.06 in premarket trading."
datetime: "2026-03-24T13:22:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280327824.md)
  - [en](https://longbridge.com/en/news/280327824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280327824.md)
---

# What's Going On With MIRA Pharma Stock Tuesday?

**MIRA Pharmaceuticals Inc.** (NASDAQ:MIRA) stock is pulling back in premarket trading on Tuesday after surging 21.74% to close sharply higher on Monday, driven by new preclinical data.

## Mira-55 Shows No CNS Side Effects

The recent study demonstrated that Mira-55 did not produce cannabinoid-like central nervous system (CNS) side effects across various validated behavioral assays, which is a significant finding for the company’s ongoing development efforts.

The data support MIRA’s strategy to advance Mira-55 towards an Investigational New Drug (IND) submission for inflammatory pain treatment.

In the study, Mira-55 was evaluated at oral doses of 10, 30, and 100 mg/kg, showing promising results compared to THC and rimonabant, with no observed psychogenic effects at any tested dose.

## Eyes Major Pain Market Opportunity

The findings indicate that Mira-55 could offer therapeutic benefits without the CNS liabilities associated with traditional cannabinoid therapies, potentially positioning it favorably in a growing market projected to reach $70.3 billion by 2030.

“The challenge in cannabinoid drug development has never been the biology-it’s been separating it from CNS side effects. We believe Mira-55 may represent an important step in that direction as we advance toward clinical development in inflammatory pain,” said **Erez Aminov**, Chairman and CEO of MIRA.

**MIRA Price Action:** Mira Pharmaceuticals shares were down 5.77% at $1.06 during premarket trading on Tuesday, according to Benzinga Pro data.

_Image via Shutterstock_

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [MIRA.US](https://longbridge.com/en/quote/MIRA.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [MIRA highlights SKNY-1 preclinical data in new publication](https://longbridge.com/en/news/286256663.md)
- [MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results](https://longbridge.com/en/news/286319406.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study | DWTX Stock News](https://longbridge.com/en/news/286772955.md)